[贝伐单抗联合铂类化疗作为非小细胞肺癌六线治疗方案的1例报道]
[Bevacizumab with platinum chemotherapy as 6th-line treatment in a case of non-small-cell lung cancer].
作者信息
Ishiura Yoshihisa, Yamamoto Hiroki, Terasaki Yasushi, Ishida Youichi, Tohge Masayoshi, Segawa Masataka, Kusajima Yoshinori, Saitoh Katsuhiko, Ishikawa Mika, Hirokami Norikazu, Kasahara Kazuo, Fujimura Masaki
机构信息
Dept. of Medical Oncology, Toyama City Hospital.
出版信息
Gan To Kagaku Ryoho. 2011 Dec;38(13):2631-3.
A 64-year-old man was admitted to our hospital for 6th-line chemotherapy. Chest X-ray film and computed tomographic (CT) scan showed right-sided pleural thickening with multiple lung tumors. Repeated treatment with carboplatin (AUC 6), paclitaxel (200 mg/m(2)) and bevacizumab (150 mg/kg) on day 1 every 21 days was effective for this patient. Chemotherapy with bevacizumab may be effective for patients with multi-recurrent adenocarcinoma.
一名64岁男性因接受第六线化疗入院。胸部X光片和计算机断层扫描（CT）显示右侧胸膜增厚并伴有多个肺部肿瘤。每21天在第1天重复使用卡铂（AUC 6）、紫杉醇（200 mg/m²）和贝伐单抗（150 mg/kg）进行治疗，对该患者有效。贝伐单抗化疗可能对多复发腺癌患者有效。
Zotero 插件